Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgocitinib is involved in various inflammatory and autoimmune diseases through JAK-dependent cytokines, and can effectively suppress multiple cytokine signaling while inhibiting itching caused by cytokines. It is widely used to treat various inflammatory diseases, including autoimmune diseases and hypersensitivity reactions.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 39,500 | |||
5 mg | 在庫あり | ¥ 123,500 | |||
10 mg | 在庫あり | ¥ 178,500 | |||
25 mg | 在庫あり | ¥ 271,000 | |||
50 mg | 在庫あり | ¥ 365,000 | |||
100 mg | 在庫あり | ¥ 498,000 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 84,500 |
説明 | Delgocitinib (JTE-052) is a specific JAK (Janus kinase) inhibitor with IC50 values of 2.8, 2.6, 13, and 58 nM for JAK1, JAK2, JAK3, and Tyk2 respectively. Delgocitinib is involved in various inflammatory and autoimmune diseases through JAK-dependent cytokines, and can effectively suppress multiple cytokine signaling while inhibiting itching caused by cytokines. It is widely used to treat various inflammatory diseases, including autoimmune diseases and hypersensitivity reactions. |
ターゲット&IC50 | JAK2:2.6 nM, JAK1:2.8 nM, TYK2:58 nM, JAK3:13 nM |
In vitro | In cytokine signaling assays, Delgocitinib demonstrates inhibition of Stat protein phosphorylation induced by IL-2, IL-6, IL-23, GM-CSF, and IFN-α, with IC50 values of 40±9, 33±14, 84±11, 304±22, and 18±3 nM. It concentration-dependently suppresses IL-2-induced T cell proliferation (IC50: 8.9±3.6 nM), exhibiting a potency comparable to Tofacitinib (IC50: 16 nM). In the enzymatic assays, Delgocitinib effective inhibition of all JAK subtypes, with IC50 values of 2.8±0.6, 2.6±0.2, 13±0, and 58±9 nM for JAK1, JAK2, JAK3, and Tyk2, respectively. Lineweaver-Burk plots display that the inhibition mode of Delgocitinib toward all JAKs is competitive with ATP (Ki: 2.1±0.3, 1.7±0.0, 5.5±0.3 and 14±1 nM for JAK1, JAK2, JAK3 and Tyk2, respectively) [1]. |
In vivo | Delgocitinib (oral; mice) effectively suppresses inflammatory responses. Orally administered Delgocitinib 1 or 6 hours before IL-2 injection, Delgocitinib can reduce the production of IFN-γ, but the efficacy of administration in the first 1 hour is higher than that of administration in the first 6 hours (ED50 = 0.24 vs. 1.3 mg/kg). Delgocitinib (oral; 0.1, 1, or 10 mg/kg; mouse) ameliorates rat collagen-induced arthritis model. Delgocitinib prevented the development of hind paw swelling and histological changes in inflammatory cell infiltration and synoviocyte proliferation before the onset of rat collagen-induced arthritis (administration starting on day 1). Delgocitinib reduced paw swelling in a dose-dependent manner after the onset of rat collagen-induced arthritis (administration starting on day 15), with improvement in paw swelling noted as early as the second day after administration. These findings suggest that Delgocitinib has a protective effect against joint inflammation and joint destruction [1]. |
別名 | JTE-052, Corectim(Delgocitinib) |
分子量 | 310.35 |
分子式 | C16H18N6O |
CAS No. | 1263774-59-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 50 mg/mL (161.11 mM)
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Delgocitinib 1263774-59-9 Angiogenesis Chromatin/Epigenetic JAK/STAT signaling Stem Cells Tyrosine Kinase/Adaptors Tyrosine Kinases JAK Inhibitor Corectim Janus kinase inhibit JTE 052 JTE-052 Corectim(Delgocitinib) JTE052 inhibitor